FabALACTICA

product-box-fabalactica

FabALACTICA® Enzyme

FabALACTICA Enzyme is supplied as a lyophilized powder with no preservatives added, and is available in 2000 unit vials for digestion of up to 2 mg IgG.

 

FabALACTICA (IgdE) is a cysteine protease that digests human IgG1 at a specific site above the hinge with no need for reducing conditions or co-factors.

 

 

 

Detailed Information

FabALACTICA is a cysteine protease that digests human IgG1 at one specific site above the hinge, generating intact Fab and Fc fragments. The name of the enzyme is derived from the pathogen Streptococcus agalactiae, where it was first discovered (Spoerry et al., 2016). The enzyme is active at pH from 6-8 and does not require reducing conditions or co-factors for activity. 

FabALACTICA is recombinantly expressed in E. coli, contains a His-tag, and the molecular weight is 70 019 Da. 

Storage and Stability

The FabALACTICA enzyme is supplied lyophilized, and is reconstituted by the addition of water. After reconstitution, FabALACTICA is stable for 1 month at +4-8°C. The product is shipped on ice, and should be stored at -20°C upon arrival.

Unit Definition

One unit digests ≥ 90% of 1 μg human IgG1, when incubated in 150 mM sodium phosphate, pH 7.0 at 37°C overnight (16-18 h).


Spoerry, C. et al., 2016. Novel IgG-Degrading Enzymes of the IgdE Protease Family Link Substrate Specificity to Host Tropism of Streptococcus Species. PloS one, 11(10), p.e0164809.

 

How to Order

For details on ordering please visit How to order. Click add to cart to buy online using a credit card.

Quotations

Please do not hesitate to contact us if you need a quotation or have inquiries on price of bulk quantities.

Documents

Product Specifications

Safety Data Sheet

Certificate of Analysis

FAQ and Support

Yes, for human IgG1 molecules both enzymes can be used in combination to generate a specific hinge peptide. The incubation time is significantly longer for FabALACTICA and it is recommended to first run the FabALACTICA digest and then add FabRICATOR for the last 30 min.
FabALACTICA does not require reducing conditions as both GingisKHAN and FabULOUS does, and allows for generation of Fab fragments from native human IgG1.

Find all FAQ here

Patent and Disclaimer

FabALACTICA®

Aspects of FabALACTICA® technology are encompassed by pending patent applications in the name of Genovis AB. The trademark FabALACTICA® is the property of Genovis AB.

For research use only. Not intended for any animal or human therapeutic or diagnostic use.

©2018 Genovis AB.